MediciNova, Inc. 2017 Form 10-K Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on small-molecule therapeutics for serious diseases with unmet medical needs. The filing covers the fiscal year ended December 31, 2017; fourth-quarter information is provided on an unaudited basis. The principal programs are MN-166 (ibudilast) for progressive multiple sclerosis, ALS and addiction-related indications, and MN-001 (tipelukast) for NASH and idiopathic pulmonary fibrosis. MN-221 and MN-029 remain earlier-stage or partner-dependent programs. No product candidate had received regulatory approval or generated product sales.
Financial performance, liquidity and capital structure
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research, development and patent expense | $4.2 million | $3.5 million |
| General and administrative expense | $8.8 million | $7.4 million |
| Total operating expenses | $13.0 million | $10.9 million |
| Operating loss | $13.0 million | $10.9 million |
| Net loss | $11.2 million | $10.9 million |
| Basic and diluted loss per share | $0.32 | $0.33 |
| Net cash used in operating activities | $6.9 million | $6.5 million |
| Cash and cash equivalents at year-end | $28.0 million | $24.1 million |
| Working capital | $25.4 million | $23.1 million |
| Total liabilities | $4.8 million | $5.3 million |
There was no meaningful revenue base against which to calculate operating or net margins. The company reported $1,000 of interest expense and had no material funded debt disclosed. Year-end stockholders’ equity was $38.6 million, and the accumulated deficit was $341.5 million. Share-based compensation was $4.5 million, or approximately 34% of operating expenses.
Material changes versus the prior comparable period
- Research, development and patent expense increased $0.7 million, primarily from increased MN-166 and MN-001 clinical activity and higher performance-based stock compensation.
- General and administrative expense increased $1.4 million, primarily from higher performance-based stock compensation and legal expenses.
- Net loss increased modestly from $10.9 million to $11.2 million, while loss per share improved to $0.32 from $0.33 because of the higher share count.
- Operating cash use increased from $6.5 million to $6.9 million.
- Financing activities provided $10.8 million, including approximately $9.9 million net proceeds from the sale of 1.69 million shares under the ATM facility and $0.4 million from warrant exercises.
- Fourth-quarter 2017 operating expenses were $3.4 million and net loss was $1.6 million, compared with fourth-quarter 2016 operating expenses of $1.4 million and net loss of $1.4 million.
- The company and its partners agreed to dissolve the Zhejiang Sunmy China joint venture; Chinese regulatory approval was obtained in December 2017.
Clinical progress, outlook and unusual items
- MN-166 completed the Phase 2b SPRINT-MS trial in progressive MS and reported a statistically significant 48% reduction in the rate of whole-brain atrophy versus placebo, with no increased rate of serious adverse events. The filing also reports positive ALS safety and tolerability results.
- The Phase 2 methamphetamine-dependence trial completed enrollment in September 2017; results were expected in the first quarter of 2018. MN-001 Phase 2 trials in NASH and IPF were ongoing.
- Management expected research and development spending to increase in 2018 and stated that available working capital was expected to fund operations through the end of 2019. This is not a profitability forecast and remains dependent on clinical spending, financing and partnering decisions.
- Management expects to seek strategic alliances to fund later-stage development and commercialization. The company has no sales or marketing infrastructure and relies on third parties for manufacturing, clinical trials and potential commercialization.
- On February 12, 2018, after year-end, the company completed a public offering of 4.42 million shares for approximately $37.4 million in net proceeds and granted underwriters an option for up to 662,983 additional shares.
- The 2017 tax benefit was $1.7 million, principally reflecting deferred-tax effects from the Tax Cuts and Jobs Act and reassessment of deferred tax liabilities. Certain tax amounts were provisional and subject to later adjustment.
- Future potential license milestone payments totaled $43.5 million, but timing is uncertain and depends on clinical, regulatory and commercialization milestones. Scheduled operating lease and remaining research-service obligations totaled $3.0 million.
Principal risks and contingencies
- Continuing losses, no approved products and no product revenue create dependence on additional equity financing, partnerships or licensing transactions.
- Clinical-trial results may not be replicated or accepted by regulators; none of the product candidates has completed the full approval process.
- The company depends heavily on MN-166 and MN-001, third-party clinical research organizations and contract manufacturers.
- Several key compounds lack composition-of-matter patent protection, and licensed rights may expire, be challenged or be terminated if contractual obligations are not met.
- Future equity issuance, including under the ATM facility, may dilute existing holders and pressure the stock price. As of December 31, 2017, 750,000 warrants with a $3.15 exercise price were outstanding and scheduled to expire May 9, 2018.
- Regulatory, safety, reimbursement, competition, product-liability, foreign-exchange and key-person risks could delay development or prevent commercialization.
Investor verification checklist
- Verify the timing and quality of subsequent clinical data for MN-166 and MN-001, including whether results support Phase 3 development.
- Reconcile cash runway assumptions with 2018 development spending, the February 2018 financing, warrant activity and any additional capital needs.
- Review dilution from the February 2018 offering, the ATM facility, outstanding warrants and stock options.
- Assess the expiration, scope and enforceability of patents and the terms of milestone and royalty obligations under the license agreements.
- Confirm the final accounting treatment of provisional Tax Cuts and Jobs Act amounts and the utilization limits on tax-loss and credit carryforwards.
- Monitor whether the company secures strategic partners capable of funding late-stage trials and commercializing any approved products.